The Role of 18F-FDG-PET for Staging and Prognostication in Patients Enrolled in the Fondazione Italiana Linfomi (FIL) MCL0208 Trial
Latest Information Update: 30 Dec 2024
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 24 Dec 2024 Planned End Date changed from 1 Jun 2024 to 31 Jan 2025.
- 03 Jun 2024 Planned End Date changed from 1 Jan 2024 to 1 Jun 2024.
- 15 Dec 2023 Status changed from recruiting to active, no longer recruiting.